Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

89%

8 trials in Phase 3/4

Results Transparency

50%

4 of 8 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 4

5(62.5%)

Phase 3

3(37.5%)

8Total

Phase 4(5)

Phase 3(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT03785223Phase 4Completed

A 14 Week, Randomized, Placebo-Controlled Cross-Over Study of Methylphenidate Hydrochloride Controlled Release Capsules in Adult ADHD With and Without Anxiety Disorder Comorbidity

Role: collaborator

NCT04741516Phase 4Unknown

Evaluation of the Effect Foquest® on Sleep in Children Aged 6-12 With ADHD

Role: collaborator

NCT03649230Completed

Observational Study on the Use of Akynzeo® in Patients Receiving HEC

Role: lead

NCT03179475Phase 4Completed

Targin® for Chronic Pain Management in Patients With Spinal Cord Injury

Role: collaborator

NCT04152629Phase 4Completed

Real World Evidence of the Efficacy and Safety of FOQUEST

Role: lead

NCT03868436Phase 4Completed

PENTHROX™ in the Canadian Emergency Department (ED)

Role: lead

NCT03618030Phase 3Completed

PRC-063 Adult Laboratory Classroom Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Role: lead

NCT03172481Phase 3Completed

PRC-063 Classroom Study in Children (6-12 Years of Age) With ADHD

Role: lead

NCT02139124Phase 3Completed

The Efficacy and Safety of PRC-063 in Adult ADHD Patients

Role: collaborator

All 9 trials loaded